Development of Resistance-Associated Mutations after Sotrovimab Administration in High-risk Individuals Infected with the SARS-CoV-2 Omicron Variant

TY - JOUR

T1 - Development of Resistance-Associated Mutations after Sotrovimab Administration in High-risk Individuals Infected with the SARS-CoV-2 Omicron Variant

AU - Birnie, Emma

AU - Biemond, Jason J.

AU - Appelman, Brent

AU - de Bree, Godelieve J.

AU - Jonges, Marcel

AU - Welkers, Matthijs R. A.

AU - Wiersinga, W. Joost

N1 - Funding Information: Funding/Support: This work was supported in part by contract HHSH250-2019-00001C from the Health Resources and Services Administration. Dr Schaubel’s work was supported by grant R01-DK070869 from the National Institutes of Health. Dr Potluri’s work was supported by grant K08-DK127250 from the National Institutes of Health. Dr Reese’s work was supported by grants K24-AI146137 and 5R01DK123041 from the National Institutes of Health. Funding Information: Conflict of Interest Disclosures: Dr Wiersinga reported receiving grant support (grant 91716475) from the Netherlands Organization of Scientific Research and personal fees (fees paid to his institution) from GlaxoSmithKline, Pfizer, Sobi, and AstraZeneca. No other disclosures were reported. Funding Information: Funding/Support: This study was funded by grant 10430142110001 from the Netherlands Organization for Health Research and Development.

PY - 2022/9/20

Y1 - 2022/9/20

UR - http://www.scopus.com/inward/record.url?scp=85135487600&partnerID=8YFLogxK

U2 - https://doi.org/10.1001/jama.2022.13854

DO - https://doi.org/10.1001/jama.2022.13854

M3 - Article

C2 - 35913747

SN - 0098-7484

VL - 328

SP - 1104

EP - 1107

JO - JAMA

JF - JAMA

IS - 11

ER -